Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:Northwood, Middlesex
Treatments:ChemotherapyHospital:Mount Vernon Cancer Centre
Drugs:Journal:Link
Date:Mar 2011

Description:

Patients:
This phase 2 trial involved women with ovarian cancer that had progressed following prior platinum-based chemotherapy. Patients were divided into two treatment groups. Group A consisted of 25 patients with a median age of 62 years. Group B was made up of 38 patients with a median age of 59 years.

Treatment:
Both groups were treated with the chemotherapy agent sagopilone, which stops cancer cells from dividing, but groups were treated using different infusion schedules. Patients in group A were administered sagopilone in 30-minute infusions. Group B received sagopilone in 3-hour infusions.

Toxicities:
The maximum reported toxicity level for group A was of grade 4, including peripheral sensory neuropathy (nerve damage; 8% of patients with grade 3-4).
The maximum toxicity level reported for group B was also of grade 4, including peripheral sensory neuropathy (21% of grade 3-4), arthritis (8%), and pain in the extremities (8%).

Results:
The median overall survival for groups A and B were 7.8 and 6.9 months, respectively.

Support:
This study was supported by Bayer Schering Pharma, makers of sagopilone.

Correspondence: Dr. G. Rustin; email: [email protected]



Back